Actualités Ionis Pharmaceuticals, - ISIS | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

CARLSBAD, Calif., Jan. 5 /PRNewswire/ -- Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials...

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

OGX-011 Phase 3 Studies in First- and Second-Line Advanced Prostate Cancer and Non-Small Cell Lung Cancer Expected to Begin in 2010 and Early 2011...

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your...

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

CARLSBAD, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

- Conference Call Webcast Thursday, August 6, 08:30 a.m. EDT at www.isispharm.com CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

OncoGenex Appoints New CFO and Board Member

VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., announced the appointment of Mr. Stephen Anderson as Chief Financial...

OncoGenex Announces Completion of $12.8 Million Venture Financing

VANCOUVER, Aug. 16 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., a clinical-stage biotechnology company developing targeted...

SAR - Universe Grp.

RNS Number:6769U ISIS Asset Management PLC 27 January 2004 FORM SAR 5 Date of disclosure 27TH JANUARY 04 DISCLOSURE UNDER NOTE 3...

Holding(s) in Company

RNS Number:6678U CeNeS Pharmaceuticals PLC 27 January 2004 CENES PHARMACEUTICALS PLC ("the Company") HOLDING IN COMPANY The Company...

Rule 8 - Restaurant Group PLC

RNS Number:6207U ISIS Asset Management PLC 26 January 2004 Date of Disclosure 26TH JANUARY 2004 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i...

Rule 8 - Morrison W.Sprmkts

RNS Number:5196U ISIS Asset Management PLC 22 January 2004 Date of Disclosure 22ND JANUARY 04 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and...

Holding(s) in Company

RNS Number:4054U Landround Plc 19 January 2004 LANDROUND PLC ("the Company") Holding in Company The Company was notified by ISIS...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ionis Pharmaceuticals, (ISIS)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ISIS Actualités

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

OncoGenex Appoints New CFO and Board Member

OncoGenex Announces Completion of $12.8 Million Venture Financing

SAR - Universe Grp.

Holding(s) in Company

Rule 8 - Restaurant Group PLC

Rule 8 - Morrison W.Sprmkts

Holding(s) in Company

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ionis Pharmaceuticals, (ISIS) Actualités

Ionis Pharmaceuticals, (ISIS)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ISIS Actualités

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

OncoGenex Appoints New CFO and Board Member

OncoGenex Announces Completion of $12.8 Million Venture Financing

SAR - Universe Grp.

Holding(s) in Company

Rule 8 - Restaurant Group PLC

Rule 8 - Morrison W.Sprmkts

Holding(s) in Company

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application